<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02812862</url>
  </required_header>
  <id_info>
    <org_study_id>15-165</org_study_id>
    <nct_id>NCT02812862</nct_id>
  </id_info>
  <brief_title>Cardiac Effects of Fixed-dose Dual Bronchodilator in Patients With Heart Insufficiency and COPD</brief_title>
  <acronym>CREATES</acronym>
  <official_title>Cardiac Effects of Fixed-dose Dual Bronchodilator in Patients With Heart Insufficiency and COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the pulmonary and cardiac effects of a LABA / LAMA
      combination therapy in patients suffering from both chronic heart failure and chronic
      obstructive pulmonary disease.

      The secondary aim of the study it to assess the safety of the LABA / LAMA combination.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparison between treatment group and control group</measure>
    <time_frame>24 months</time_frame>
    <description>major adverse cardiac events, mortality &amp; hospitalization</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <description>50 male and female patients suffering from chronic heart failure and chronic obstructive pulmonary disease.
Ultibro/ Breezhaler combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>50 male and female patients suffering from chronic heart failure but not COPD and NOT receiving LAMA/ LABA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ultibro/ Breezhaler</intervention_name>
    <description>LABA/ LAMA combination therapy a combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent</description>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>Long-acting ß-agonist (LABA)</other_name>
    <other_name>Long-acting anti-muscarinergic agent (LAMA)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        50 male and female patients suffering from chronic heart failure and chronic obstructive
        pulmonary disease.

        50 male and female patients suffering from chronic heart failure but not COPD and NOT
        receiving LAMA/ LABA
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults who are contractually capable and mentally able to understand and follow the
             instructions of the study personnel

          -  Symptomatic with regard to dyspnea (NYHA II and more)

          -  Treatment group: COPD (FEV1/FVC ratio &lt;70%, FEV1 &lt; 80%)

          -  Control group: No COPD, no LAMA or LABA

          -  Chronic heart failure (ejection fraction &lt; 40%)

          -  Stability of CHF during the preceding 3 months

          -  Male or female aged &gt; 18 years

          -  Written informed consent prior to study participation

          -  The subject is willing and able to follow the procedures outlined in the protocol

        Exclusion Criteria:

          -  Lack of informed consent

          -  Pregnant and lactating females

          -  Acute exacerbation of COPD, acute respiratory failure (pH &lt; 7,35 and/ or respiratory
             rate &gt; 30/min)

          -  Unstable heart failure or planned change in medication

          -  Not symptomatic

          -  Patient has been committed to an institution by legal or regulatory order

          -  Participation in a parallel interventional clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Dreher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital RWTH Aachen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Dreher, MD</last_name>
    <phone>+49 241 80 88763</phone>
    <email>mdreher@ukaachen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Cornelissen, MD</last_name>
    <phone>+49 241 80 85060</phone>
    <email>ccornelissen@ukaachen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinic of Cardiology, Angiology, Pneumology and Intensive Medicine, University Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <state>North Rhine Westphalia</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Dreher, MD</last_name>
      <phone>+49 241 80 35002</phone>
      <email>mdreher@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Christian Cornelissen, MD</last_name>
      <phone>+49 241 80 85060</phone>
      <email>ccornelissen@ukaachen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Dreher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, Banerji D. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013 Dec;42(6):1484-94. doi: 10.1183/09031936.00200212. Epub 2013 May 30.</citation>
    <PMID>23722616</PMID>
  </reference>
  <reference>
    <citation>Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, Chen H, Banerji D. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med. 2013 Oct;107(10):1558-67. doi: 10.1016/j.rmed.2013.05.016. Epub 2013 Jul 16.</citation>
    <PMID>23867808</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <last_update_submitted>August 8, 2016</last_update_submitted>
  <last_update_submitted_qc>August 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchodilator Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

